EFTA01468515

Date

Unknown

Source

DOJ Data Set 10

Reference

efta-01468515

Pages

Persons

Integrity

Summary

Ask AI About This Document

0upvotesShare

Post Reddit

Save Post Watch

Extracted Text (OCR)

EFTA Disclosure

Text extracted via OCR from the original document. May contain errors from the scanning process.

Subject: $/Y and Biotech [C] From: Tazia Smith ‹ > Date: Wed, 23 Apr 2014 11:54:05 -0400 To: [email protected] Cc: Paul Morris Nav Gupta Vinit Sahni Vahe Stepanian Classification: Confidential Jeffrey - Just posting you on your biotech basket - earnings a positive catalyst reversing that downtrend in Gilead. Biogen reported this morning (bottom line miss, top-line beat), stock has come in from pre-market highs of $310, now —$303 (3-day chart below). Just a reminder that your $Y 102.5 call is going to expire 5/1. In speaking with Nav and Vinit, they looked at lot of weaker-yen iterations but their view is vols are too low and there is an absence of catalysts to present a compelling trade at this moment to roll into; Nav will email you directly to highlight entry points on a trade when he sees one. As you know, you've got your zero-cost option on for some exposure to yen weakness. Source: Pershing, LLC and Bloomberg Biogen - 3-day inter-day chart Tazia Smith Director I Key Client Partners - US DB Securities Inc Deutsche Asset & Wealth Management 345 Park Avenue, 10154-0004 New York, NY, USA EFTA01468515 Tel. Fax Mobile +1 Email EFTA01468516

Technical Artifacts (1)

View in Artifacts Browser

Email addresses, URLs, phone numbers, and other technical indicators extracted from this document.

Email[email protected]

EFTA01468515

Summary

Ask AI About This Document

Extracted Text (OCR)

Technical Artifacts (1)

Related Documents (6)

EFTA Document EFTA01473151

EFTA Document EFTA01453366

From: "Jeffrey E." <[email protected]>

EFTA01344254

DS9 Document EFTA00372077

EFTA Document EFTA01450840

Forum Discussions